Vera Therapeutics, Inc. was reported as having 1,229,525 shares of Class A Common Stock beneficially owned by Point72-affiliated filers, representing 1.7% of the class as of March 31, 2026. The reported holdings include 17,800 shares issuable upon exercise of call options held by the managed fund. The filing is a joint Schedule 13G by Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen and states that the reporting persons have shared voting and dispositive power over the 1,229,525 shares.
Positive
None.
Negative
None.
Insights
Point72-affiliated entities report a passive, 1.7% beneficial stake in Vera Therapeutics as of March 31, 2026.
Row 9 shows 1,229,525 shares and Item 4 ties that figure to shared voting and dispositive power. The filing is submitted under Rule 13d-1(k) via a Joint Filing Agreement and indicates passive reporting rather than activist intent.
Holding includes 17,800 shares issuable upon exercise of call options; the filing notes the positions are managed through an investment fund. Subsequent filings would show any change in level or intent.
Key Figures
Beneficial ownership:1,229,525 sharesPercent of class:1.7%Options exercisable into shares:17,800 shares+1 more
4 metrics
Beneficial ownership1,229,525 sharesAmount reported in Row 9; as of March 31, 2026
Percent of class1.7%Percent of Class A Common Stock reported in Item 4(b)
Options exercisable into shares17,800 sharesIncluded in reported total as issuable upon exercise of call options
Reporting dateMarch 31, 2026Close of business date for ownership figures in Item 4
"This statement is filed by: (i) Point72 Asset Management ..."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Joint Filing Agreementregulatory
"Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement"
beneficially ownedfinancial
"The Reporting Persons may have been deemed to be the beneficial owner of more than five percent"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Vera Therapeutics, Inc.
(Name of Issuer)
Class A Common Stock, par value $0.001 per share
(Title of Class of Securities)
92337R101
(CUSIP Number)
03/25/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
92337R101
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,229,525.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,229,525.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,229,525.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Includes 17,800 shares of Class A Common Stock (as defined in Item 2(a)) issuable upon exercise of call options.
SCHEDULE 13G
CUSIP Number(s):
92337R101
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,229,525.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,229,525.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,229,525.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.7 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Includes 17,800 shares of Class A Common Stock issuable upon exercise of call options.
SCHEDULE 13G
CUSIP Number(s):
92337R101
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,229,525.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,229,525.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,229,525.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.7 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Includes 17,800 shares of Class A Common Stock issuable upon exercise of call options.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Vera Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
2000 Sierra Point Parkway, Suite 1200, Brisbane, CA 94005
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of class A common stock, par value $0.001 per share ("Class A Common Stock"), of Vera Therapeutics, Inc. held by (and underlying options held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Class A Common Stock held by (and underlying options held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Class A Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Cubist Systematic Strategies, LLC is a relying adviser on the Form ADV of Point72 Asset Management and acts as a sub-advisor with respect to a portion of the Class A Common Stock reported herein.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Class A Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
92337R101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
On the date of the event which requires the filing of this Schedule 13G, the Reporting Persons may have been deemed to be the beneficial owner of more than five percent of the shares of Class A Common Stock.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Class A Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Class A Common Stock reported herein.
(b)
Percent of class:
1.7 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Point72-affiliated filers report a beneficial ownership of 1,229,525 shares, equal to 1.7% of Class A Common Stock as of March 31, 2026. The amount includes 17,800 shares issuable upon exercise of call options.
Who filed the Schedule 13G for VERA?
The statement is filed jointly by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen under a Joint Filing Agreement, reporting shared voting and dispositive power over the securities.
Does the filing indicate active control or ownership of VERA shares?
The filing states the reporting persons have shared voting and dispositive power over the 1,229,525 shares held by an investment fund they manage; it does not assert direct sole ownership of Class A shares.
Are there derivative or exercisable securities included in the reported total?
Yes. The reported total explicitly includes 17,800 shares of Class A Common Stock issuable upon exercise of call options, as noted in the cover-page comment and Item 4 disclosure.
What address is listed for the reporting persons in the VERA filing?
The principal business office for the reporting persons is listed as 72 Cummings Point Road, Stamford, CT 06902, as provided in Item 2(b) of the filing.
